Does anyone have any knowledge re how the Glaxo-Apotex AG deal for fonda may work? Do Glaxo manufature & 'sell' to Apotex? Do Apotex manufacture & market, & pay Glaxo a royalty of some type? Or what?
I haven't personally seen any hard data (can't afford IMS or Bloomberg!), but the 'word' seems to be that, by volume, Arixtra sales are now less than 15% by volume of total US sales; and much much less than that in the higher value retail market. If roughly correct, for the overall market, DRL are around 25%, then Apotex must be about 60%.
So, it escapes me what's in it for Glaxo to keep the AG arrangement with Apotex going?
authorised generics
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable